| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9550036 | IMPEL NEUROPHARMA | Nasal drug delivery device |
Sep, 2032
(8 years from now) | |
| US10507295 | IMPEL NEUROPHARMA | Nasal drug delivery device |
Dec, 2032
(9 years from now) | |
| US10940278 | IMPEL NEUROPHARMA | Nozzles for nasal drug delivery |
Jan, 2033
(9 years from now) | |
| US9919117 | IMPEL NEUROPHARMA | Nozzles for nasal drug delivery |
Mar, 2033
(9 years from now) | |
| US11266799 | IMPEL NEUROPHARMA | In-line nasal delivery device |
Nov, 2036
(13 years from now) | |
| US11185497 | IMPEL NEUROPHARMA | Intranasal delivery of dihydroergotamine by precision olfactory device |
Jan, 2039
(15 years from now) | |
Trudhesa is owned by Impel Neuropharma.
Trudhesa contains Dihydroergotamine Mesylate.
Trudhesa has a total of 6 drug patents out of which 0 drug patents have expired.
Trudhesa was authorised for market use on 02 September, 2021.
Trudhesa is available in spray, metered;nasal dosage forms.
Trudhesa can be used as nasal administration of dihydroergotamine mesylate by metered spray for the acute treatment of migraine with or without aura.
The generics of Trudhesa are possible to be released after 04 January, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Sep 2, 2024 |
Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient
Market Authorisation Date: 02 September, 2021
Treatment: Nasal administration of dihydroergotamine mesylate by metered spray for the acute treatment of migraine with or without aura
Dosage: SPRAY, METERED;NASAL
TRUDHESA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic